CA2505389A1 — Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2004-05-21 · 22y expired
What this patent protects
The present invention relates to substituted xanthines of general formula (see formula I), wherein R1 to R4 are defined as in claim 1, the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological propertie…
USPTO Abstract
The present invention relates to substituted xanthines of general formula (see formula I), wherein R1 to R4 are defined as in claim 1, the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.